Clinical study with cladribine completed

We have succesfully completed phase I study for female patients suffering from relapsing multiple sclerosis.

The aim of the study was to examine the effect of cladribine used in the treatment of relapsing multiple sclerosis on an oral contraceptive containing ethinyl estradiol and levonorgestrel.

Cladribine is a synthetic purine nucleoside that acts as an antineoplastic agent with immunosuppressive effects. Cladribine differs structurally from deoxyadenosine only by the presence of a chlorine atom at position 2 of the purine ring, which results in resistance to enzymatic degradation by adenosine deaminase.

Go back

News

6th anniversary

This week we celebrate our 6th anniversary. Together with our CEO, clinical team and company's friends, we had a pleasure of being at Aga Zaryan's concert and fancy diner.

Read more …

Webinar

We are constantly improving our knowledge to assure the best possible quality of our services.

Read more …

Medical Guide Where to Treat 2022

On 29th of April, a special thematic supplement was published in the Polska The Times and Miasto.pl newspaper - Medical Guide Where to Treat 2022...

Read more …

BRG Support for Ukraine

We are deeply moved and concerned by the events in Ukraine. As a clinical site, focused on the development of medicine and helping other people,...

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲